CD28 and cancer: T cells can be engineered to express chimeric antigen receptors (CARs) that specifically target antigens on the surface of cancer cells, and signal through protein elements derived from both the TCR and CD28 or other co-stimulatory receptors (Chen and Flies, 2013; Globerson Levin et al., 2021).